On December 9, 2016 BioInvent International (OMXS: BINV) reported that it has decided to terminate its current clinical Phase II study with BI-505 in multiple myeloma (Press release, BioInvent, DEC 9, 2016, http://www.bioinvent.com/media-centre/press-releases/release/?ReleaseID=D31A6036F0928688 [SID1234517021]). The decision follows BioInvent’s review and discussion with the US Food & Drug Administration (FDA), who put BI-505 on full clinical hold in November 2016. Schedule your 30 min Free 1stOncology Demo! The terminated trial, which was performed in collaboration with Penn Medicine, targeted a specific population of multiple myeloma patients undergoing autologous stem cell transplantation with high-dose melphalan.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!